07.01.09
Daily supplementation with ProbioKid, from Institut Rosell-Lallemand, reduced the risks of common infections in children, according to a recent randomized, double-blind, placebo-controlled study.
The study was conducted during the winter of 2006-2007 and involved 135 healthy, school-age children who had suffered from at least three episodes of ear-nose-throat (ENT), bronchopulmonary or gastric disorder during the course of the previous winter. They supplemented daily for three months.
Fifty percent of the children in the synbiotic group did not develop any ENT, bronchopulmonary or gastric disorder episodes during the winter compared to 33% of children in the placebo group. This represents a 25% reduction in the relative risk of infectious disease in the ProbioKid group compared to the placebo group. In addition, 26% of children in the synbiotic group missed at least one day of school versus 43% in the placebo group. For further information: www.lallemand.com
The study was conducted during the winter of 2006-2007 and involved 135 healthy, school-age children who had suffered from at least three episodes of ear-nose-throat (ENT), bronchopulmonary or gastric disorder during the course of the previous winter. They supplemented daily for three months.
Fifty percent of the children in the synbiotic group did not develop any ENT, bronchopulmonary or gastric disorder episodes during the winter compared to 33% of children in the placebo group. This represents a 25% reduction in the relative risk of infectious disease in the ProbioKid group compared to the placebo group. In addition, 26% of children in the synbiotic group missed at least one day of school versus 43% in the placebo group. For further information: www.lallemand.com